Small-Molecule SLC6A19 Inhibitors for Phenylalanine Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for phenylketonuria (PKU), such as enzyme co-factor and enzyme substitution therapy, are not effective for all patients and carry potential adverse events, and there is a need for alternative methods to manage phenylalanine levels effectively.
Innovation Solution
Development of compounds that modulate SLC6A19 transport, specifically those with the structure of Formula (I), to regulate amino acid levels and treat or prevent disorders associated with phenylalanine metabolism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme co-factor and enzyme substitution therapy are used to treat PKU, then phenylalanine metabolism is improved, but adverse events and lack of effectiveness in all patients occur
Solution Approach 1:
The patent introduces SLC6A19 as an intermediary target to indirectly regulate phenylalanine levels. Instead of directly replacing or cofactoring PAH, the invention modulates amino acid transport through SLC6A19 in the kidney proximal tubule, creating a downstream control mechanism that avoids the adverse events associated with direct PAH therapy while achieving the same metabolic correction goal
Solution Approach 2:
The invention changes the therapeutic parameter from direct enzyme activity modulation to transport protein modulation. By developing small molecule inhibitors that bind to SLC6A19 and alter its transport function, the patent shifts the mechanism of action from enzyme replacement to transport regulation, thereby achieving phenylalanine level control through a different physiological parameter that avoids known adverse events
2Reliability
If strict diet is enforced to manage phenylalanine levels, then blood phenylalanine levels are controlled, but quality of life and ease of operation are reduced
Solution Approach 1:
The patent enables the body's own kidney transport system to automatically regulate phenylalanine levels through pharmacological modulation of SLC6A19. Once the small molecule inhibitor is administered, the system self-regulates amino acid reabsorption without requiring continuous dietary monitoring or patient intervention, thereby maintaining reliable phenylalanine control while significantly improving ease of operation and quality of life
3Reliability
If SLC6A19 transport is modulated to regulate amino acid levels, then therapeutic effectiveness is improved, but device complexity and manufacturing complexity increase
Solution Approach 1:
The patent employs small molecule inhibitors that can be synthesized relatively simply and administered systemically, replacing the need for complex enzyme replacement therapies requiring cold chain storage and administration. These small molecules, while structurally varied, can be produced through standard pharmaceutical synthesis and delivered via conventional routes, reducing overall treatment complexity despite the molecular complexity of the compounds themselves
Data Source
AI summary
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.